Chun (Michael) Chen
Senior Translational Medicine Scientist Burning Rock Dx
Seminars
Thursday 5th February 2026
ctDNA in Oncology Development: From Dynamic Monitoring to Emerging Clinical Endpoints
11:25 am
- Burning Rock’s ctDNA platforms enable real-time assessment of tumor dynamics and molecular evolution, empowering more precise and adaptive clinical development strategies
- Through both tumor-informed and tumor-naïve MRD assays, Burning Rock provides robust solutions for residual disease detection and translational research in solid tumors
- With MRD already accepted as an endpoint in hematologic malignancies, emerging data from solid tumors may soon position ctDNA-based MRD as a surrogate endpoint to accelerate oncology trials
